|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
| |||||||||||||||||||
|
|
 |
|
|
|
|
|
|
|
|
 |
||||||
|
Victoria G. Hale, Ph.D.
(Chair) Former President Commercial Operations Bernardita Mendez, Ph.D. President Herbert D. Montgomery Director, Infectious Disease
|
Leslie Z. Benet, Ph.D., Professor, Department of Biopharmaceutical
Sciences & Pharmaceutical Chemistry, University of California at San Francisco
(UCSF), is an internationally recognized authority on drug development.
Dr. Benet is former Chair of the Departments of Pharmacy and Biopharmaceutical
Sciences at UCSF (1978-1995), and currently lectures at UCSF on drug development
and the operation of the FDA. He has founded three start-up pharmaceutical
companies and holds nine US patents on pharmaceutical compounds. He is
past chair of the International Pharmaceutical Federation, and is a member
of the Institute of Medicine of the National Academy of Sciences. He has
served as Chair of the FDA Expert Panel on Individual Bioequivalence,
and on scientific advisory boards to a number of corporate and foundation
boards, including Roche Bioscience and the American Foundation for Pharmaceutical
Education.
 Frederick
W. Kyle, Former President Commercial Operations, Smithkline Beecham Pharmaceuticals, , is a seasoned executive, board member, and consultant to the pharmaceutical industry, with more than four decades of experience, including assignments in the developing world. Mr. Kyle’s experience spans large companies, such SmithKline Beecham Plc to small therapeutics and consulting companies, and to the nonprofit sector where he managed the Red Cross' blood and tissue donation program in the U.S. For more than a decade he was with SmithKline Beecham, serving in his last position as president of the pharmaceuticals division’s worldwide commercial operations and a member of the corporation’s board of directors. Mr. Kyle received his bachelor’s degree in economics from Swarthmore where he currently serves as a trustee.
 Bernardita
Mendez, Ph.D., President, Fundación Ciencia para
la Vida (Science for Life Foundation) in Santiago, Chile. This private nonprofit organization was founded to stimulate the use of biotechnology by export-oriented industries in Chile with high economic impact. Her strong biotechnology background also includes more than a decade with Chiron Corporation in Emeryville, Calif., as vice president, Regulatory and Quality Affairs, a corporate officer and a member of the Executive Committee. Dr. Mendez is adjunct professor at the Universidad Andrés Bello and at Pontificia Universidad Católica de Chile, both in Santiago. She is a Board member of several profit and non profit organizations and a member of the National Council for Innovation, convened by the President of Chile. She received B.S. and M.S. degrees in biology from the University of Chile. She earned her Ph.D. in cell biology from Pontificia Universidad Católica de Chile, followed by a postdoctoral fellowship with the department of biochemistry at the University of California, Berkeley. Dr. Mendez has been widely recognized in the field of biological sciences and has been published in journals and publications worldwide.
Herbert D. Montgomery, Vice Chairman and Executive Officer of Lightpost Holdings, LLC, (holding company of the Thomas Kinkade Company and other entities), is a gifted business leader and strategist. Prior to joining Lightpost Holdings, Mr. Montgomery was the Executive Vice President, Chief Financial Officer and Treasurer of Standard Media International, Inc., publisher of The Industry Standard magazine. Over the last 25 years, Mr. Montgomery has served in executive positions of several technology and services companies, including Cotelligent, Guy F. Atkinson Company, Harding Lawson Associates, and National Semiconductor. An experienced executive and strategist, Mr. Montgomery specializes in: high growth, technology environments; strategic acquisitions; taken three companies public, and one from public to private; and successfully completed several turnarounds. Mr. Montgomery holds a B.S. degree in Finance and a M.S. degree in Business Administration from California State University, Northridge.
 Keith Olson, Director Financial Planning & Analysis, Bill and Melinda Gates Foundation, currently manages the financial team that oversees the foundation’s annual budget, prices foundation strategic plans, maintains its financial reporting framework, and consults with its program staff on financial issues. Mr. Olson has garnered his various corporate finance experience by serving in several executive positions which have included private debt and equity investing, mergers and acquisitions, business plan development, and joint venture structuring. Prior to joining the foundation, Mr. Olson served in finance positions with Citibank, Prudential Capital Group, and KPMG. Mr. Olson holds B.S. degrees in Economics and Industrial Management from Purdue University and received his Masters in Business Administration from Duke University's Fuqua School of Business.
 Regina Rabinovich, MD, MPH Director, Infectious Diseases, Global Health Program, Bill & Melinda Gates Foundation. Regina received an MD Southern Illinois University and trained in pediatrics at the University of North Carolina (UNC) in Chapel Hill. After a one-year stint in administration as chief resident, she completed 3 years of training in maternal and child health, preventive medicine, epidemiology, and obtained an MPH from UNC. She joined the epidemiology training program at the National Institute of Allergy and Infectious Diseases (NIAID) as a fellow. She held various positions at NIAID, including chief of the clinical and regulatory affairs branch of the division of microbiology and infectious diseases. Before joining the Bill & Melinda Gates Foundation she was director of the Malaria Vaccine Initiative for the Program for Appropriate Technology in Health (MVI/PATH). In her current position as director of infectious diseases, she is involved in the development of strategies and their implementation for the prevention, treatment and control of diseases of particular relevance to global health, focusing on malaria, pneumonia, diarrhea, human papillomavirus (HPV), and the more classic “neglected diseases”. The scope includes drug and vaccine research, development and introduction, clinical trials and control programs.
|
||||||
|
|||||||
|
 |
|
|
||||
|
|
|
 |
 |
 |
|
||
 |
|
||||||
| ©2008 iOWH. All rights reserved. | Design: Formative & A Bear Knows How | |
|||||
|
|
|
|
|
|
|
|
Victoria Hale, Ph.D., Founder & Chair of the Board of
Directors of the Institute for OneWorld Health. Dr. Hale
established her expertise in all stages of bio/pharmaceutical drug development
at the US Food and Drug Administration, Center for Drug Evaluation and
Research (FDA), and at Genentech, Inc., the world's first biotechnology company. She earned
her Ph.D. in Pharmaceutical Chemistry from the University of California, San Francisco (UCSF). She presently maintains an Adjunct Associate Professorship
in Biopharmaceutical Sciences at UCSF, is an Advisor to the WHO for building
ethical review capacity in the developing world, and has served as an
expert reviewer to the NIH on the topic of biodiversity. Dr. Hale's recent honors
include being named Executive of the Year by Esquire Magazine and receiving The Economist Innovation Award for Social and Economic Innovation, as well as being named one of 2004's “Most Outstanding Social Entrepreneurs"
by the Schwab Foundation for Social Entrepreneurship in Switzerland.